Kids’ self-reports of symptoms, side effects reliableJune 24, 2017Lymphoma & Plasma Cell DisordersHematology NursingRelated Issues
Chemo-free triplet produces ‘favorable’ results in advanced diseaseJune 23, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Inhibitor elicits responses in heavily pretreated FL, DLBCLJune 22, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
New frontline treatments needed for Hodgkin lymphomaJune 22, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Biosimilar rituximab approved in EuropeJune 20, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
CAR T cells plus ibrutinib induce CLL remissionsJune 17, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAggressive Lymphomas
Addition of ublituximab to ibrutinib improves response in r/r CLLJune 7, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAggressive Lymphomas
Severe health conditions decrease among childhood cancer survivorsJune 4, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Differences emerge in new guidelines for managing FN in kidsJune 3, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsTransplantationAMLALLAggressive Lymphomas
BLA for CAR T-cell therapy granted priority reviewMay 29, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
EC grants drug orphan designation for CTCLMay 25, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Why fewer blood cancer patients receive hospice careMay 23, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAggressive Lymphomas
Global study reveals healthcare inequity, preventable deathsMay 23, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersRelated IssuesHodgkin Lymphoma
FDA grants priority review to NDA for copanlisibMay 18, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Compound could treat lymphoma, myelomaMay 17, 2017Lymphoma & Plasma Cell DisordersMultiple MyelomaNon-Hodgkin LymphomaAggressive Lymphomas
